Echocardiography and impedance cardiography as determinants of successful slow levosimendan infusion in advanced older heart failure patients

作     者：Gaetano Ruocco Guido Pastorini Mauro Feola Gaetano Ruocco;Guido Pastorini;Mauro Feola

作者机构：Cardiology UnitRiuniti of Valdichiana HospitalUSL-SUD-EST ToscanaMontepulcianoSienaItaly Cardiology UnitRegina Montis Regalis HospitalASL-CN1MondovìCuneoItaly 

出 版 物：《Journal of Geriatric Cardiology》 (老年心脏病学杂志（英文版）)

年 卷 期：2021年第18卷第12期

页      面：1058-1062页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：patients infusion mortality 

摘      要：Despite new therapeutic options,patients with heart failure(HF)still progress to advanced *** particular,patients who developed a severe left ventricular(LV)systolic and/or diastolic dysfunction with higher degree of NYHA class,recurrent hospitalizations for HF and showing a severe impairment of exercise capacity were defined as“advanced HF.[1]Levosimendan was recently approved in order to treat patients hospitalized for acute decompensated HF(ADHF)with severe systolic *** pharmacolo-gical effects of levosimendan consists of inotropy,vasodilatation and cardioprotection increasing of calcium sensitivity.[2]These effects should be mon-itored with echocardiography.[3]In particular,in ad-vanced HF patients,levosimendan showed positive effects in reducing mortality and three months hos-pitalization;about quality of life and symptoms im-provement,levosimendan showed contrasting ef-fect among the studies on advanced HF patients available.